These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 11373411)

  • 1. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
    Butty VL; Roux-Lombard P; Garbino J; Dayer JM; Ricou B;
    Eur Cytokine Netw; 2003; 14(1):15-9. PubMed ID: 12799209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of immunomodulating therapy on morbidity in patients with severe sepsis.
    Pittet D; Harbarth S; Suter PM; Reinhart K; Leighton A; Barker C; Macdonald F; Abraham E
    Am J Respir Crit Care Med; 1999 Sep; 160(3):852-7. PubMed ID: 10471608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
    Neurology; 1999 Aug; 53(3):457-65. PubMed ID: 10449104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.
    Angstwurm MW; Engelmann L; Zimmermann T; Lehmann C; Spes CH; Abel P; Strauss R; Meier-Hellmann A; Insel R; Radke J; Schüttler J; Gärtner R
    Crit Care Med; 2007 Jan; 35(1):118-26. PubMed ID: 17095947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
    Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
    J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of underlying mechanism and genotype on outcome of sepsis trials.
    McIntyre L; Walley KR
    Crit Care Med; 2001 Mar; 29(3):677-9. PubMed ID: 11373447
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
    Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
    Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
    Panacek EA; Marshall JC; Albertson TE; Johnson DH; Johnson S; MacArthur RD; Miller M; Barchuk WT; Fischkoff S; Kaul M; Teoh L; Van Meter L; Daum L; Lemeshow S; Hicklin G; Doig C;
    Crit Care Med; 2004 Nov; 32(11):2173-82. PubMed ID: 15640628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality.
    Presneill JJ; Waring PM; Layton JE; Maher DW; Cebon J; Harley NS; Wilson JW; Cade JF
    Crit Care Med; 2000 Jul; 28(7):2344-54. PubMed ID: 10921563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
    Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
    J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
    Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
    N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
    Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.
    Harbarth S; Garbino J; Pugin J; Romand JA; Lew D; Pittet D
    Am J Med; 2003 Nov; 115(7):529-35. PubMed ID: 14599631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.
    Staubach KH; Schröder J; Stüber F; Gehrke K; Traumann E; Zabel P
    Arch Surg; 1998 Jan; 133(1):94-100. PubMed ID: 9438767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
    Cohen J; Carlet J
    Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
    Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
    Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.
    Eisele B; Lamy M; Thijs LG; Keinecke HO; Schuster HP; Matthias FR; Fourrier F; Heinrichs H; Delvos U
    Intensive Care Med; 1998 Jul; 24(7):663-72. PubMed ID: 9722035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.